In Vitro Diagnostics Market

The secondary research process involved comprehensive analysis of regulatory databases, peer-reviewed medical journals, clinical laboratory publications, and authoritative health organizations. Key sources included the US Food & Drug Administration (FDA) Center for Devices and Radiological Health, European Medicines Agency (EMA) In Vitro Diagnostic Regulation (IVDR), Centers for Medicare & Medicaid Services (CMS), Centers for Disease Control and Prevention (CDC) Laboratory Division, National Institutes of Health (NIH), World Health Organization (WHO) Global Health Observatory and Essential Diagnostics List, ClinicalTrials.gov, National Center for Biotechnology Information (NCBI/PubMed), Agency for Healthcare Research and Quality (AHRQ), European Centre for Disease Prevention and Control (ECDC), EU Eurostat Health Database, and national health ministry reports from key markets. These sources were used to collect diagnostic testing statistics, regulatory approval data (510(k), PMA, CE-IVD), clinical safety and efficacy studies, laboratory automation trends, and market landscape analysis for immunoassay platforms, molecular diagnostics (PCR/NGS), clinical chemistry analyzers, hematology systems, microbiology testing, and point-of-care devices.

Additional authoritative sources included the American Association for Clinical Chemistry (AACC), Association for Molecular Pathology (AMP), American Society for Clinical Pathology (ASCP), Clinical Laboratory Management Association (CLMA), AdvaMedDx, European Diagnostic Manufacturers Association (EDMA), American Diabetes Association (ADA), and College of American Pathologists (CAP) proficiency testing data.

The following sources provided reimbursement classification (CPT/HCPCS), laboratory accreditation standards, and industry benchmarking data for hospital laboratories, clinical reference labs, and physician office labs. Additionally, they provided procedure volume metrics.

Qualitative and quantitative insights were obtained by interviewing supply-side and demand-side stakeholders during the primary research process. The supply-side sources comprised CEOs, VPs of Research & Development, regulatory affairs chiefs, marketing and sales directors, and commercial directors from IVD manufacturers, reagent suppliers, and diagnostic instrument OEMs. Demand-side sources included pathologists who were board-certified, clinical laboratory directors, medical technologists, hospital system laboratory managers, procurement leads from integrated delivery networks (IDNs), blood bank supervisors, and molecular diagnostics specialists from academic medical centers, commercial reference laboratories, hospitals, and ambulatory diagnostic centers. Market segmentation was validated, product pipeline timelines were confirmed, and insights regarding laboratory automation adoption, pricing strategies, reimbursement dynamics, and point-of-care decentralization trends were obtained through primary research.

Primary Respondent Breakdown:

• By Designation: C-level Primaries (32%), Director Level (30%), Others (38%)

• By Region: North America (38%), Europe (25%), Asia-Pacific (28%), Rest of World (9%)

Revenue mapping and diagnostic test volume analysis were employed to determine the global market valuation. The methodology comprised the following:

• Identification of over 50 key manufacturers in North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa

• Product mapping for software/data management solutions, instruments/analyzers, and reagents & consumables

• Technology planning in the following fields: immunoassay (ELISA, chemiluminescence), molecular diagnostics (PCR, sequencing, isothermal amplification), clinical chemistry, hematology, microbiology, coagulation testing, and blood glucose monitoring

• Examination of annual revenues that are specific to IVD product portfolios and service contracts, as reported and modeled

• In 2024, the coverage of manufacturers will account for 75-80% of the global market share.

• Segment-specific valuations across laboratory and point-of-care settings are derived through extrapolation using bottom-up (test volume × ASP by country/setting) and top-down (manufacturer revenue validation) approaches.